clonidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, clonidine derivatives 704 4205-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clonidine
  • clonidine hydrochloride
  • clonidine HCl
An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
  • Molecular weight: 230.09
  • Formula: C9H9Cl2N3
  • CLOGP: 1.73
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 36.42
  • ALOGS: -2.68
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.45 mg O
0.45 mg P
0.10 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.17 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 62 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.56 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 3, 1974 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Temperature regulation disorder 326.07 10.70 136 56318 4091 50544579
Completed suicide 284.87 10.70 520 55934 131369 50417301
Food allergy 244.07 10.70 137 56317 8000 50540670
Coeliac disease 235.75 10.70 137 56317 8548 50540122
Bursitis 188.68 10.70 173 56281 21962 50526708
Immunodeficiency 169.30 10.70 137 56317 14691 50533979
Cardiac failure congestive 158.83 10.70 314 56140 84068 50464602
Hypertension 146.82 10.70 543 55911 210660 50338010
Drug withdrawal syndrome 143.65 10.70 158 56296 24923 50523747
Hypertensive crisis 130.39 10.70 112 56342 13042 50535628
Hyperhidrosis 128.22 10.70 298 56156 89128 50459542
Mental status changes 127.80 10.70 179 56275 36093 50512577
Bradycardia 122.71 10.70 241 56213 64185 50484485
Blood pressure inadequately controlled 108.14 10.70 65 56389 4315 50544355
Synovitis 104.75 10.70 9 56445 123856 50424814
Rash erythematous 102.54 10.70 158 56296 34694 50513976
Blood pressure increased 96.34 10.70 347 56107 132785 50415885
Application site rash 94.06 10.70 48 56406 2309 50546361
Glossodynia 93.49 10.70 10 56444 115559 50433111
Drug intolerance 92.30 10.70 66 56388 219038 50329632
Application site pruritus 90.78 10.70 55 56399 3704 50544966
Fluid retention 89.89 10.70 184 56270 50465 50498205
Joint swelling 88.41 10.70 86 56368 245200 50303470
Overdose 88.10 10.70 278 56176 99449 50449221
Systemic lupus erythematosus 86.12 10.70 25 56429 140597 50408073
Nephrogenic systemic fibrosis 83.73 10.70 55 56399 4267 50544403
Infusion related reaction 81.17 10.70 44 56410 169513 50379157
Cerebrovascular accident 80.95 10.70 261 56193 94419 50454251
Product adhesion issue 80.51 10.70 54 56400 4338 50544332
Poisoning 79.43 10.70 83 56371 12346 50536324
Maternal exposure during pregnancy 78.64 10.70 40 56414 159738 50388932
Sinus bradycardia 77.12 10.70 84 56370 13099 50535571
Arthropathy 77.02 10.70 40 56414 157866 50390804
Alopecia 76.14 10.70 97 56357 244950 50303720
Neovascularisation 76.13 10.70 32 56422 981 50547689
Pericarditis 74.72 10.70 3 56451 78686 50469984
Hypertensive encephalopathy 74.21 10.70 27 56427 557 50548113
Body tinea 70.93 10.70 33 56421 1294 50547376
Upper respiratory tract infection 69.85 10.70 196 56258 65702 50482968
Hypotension 68.27 10.70 473 55981 234996 50313674
Application site erythema 67.31 10.70 49 56405 4489 50544181
Withdrawal hypertension 63.63 10.70 17 56437 117 50548553
Application site irritation 59.01 10.70 31 56423 1584 50547086
Sedation 57.63 10.70 114 56340 30496 50518174
Wound 57.49 10.70 23 56431 105771 50442899
Constipation 56.74 10.70 378 56076 185330 50363340
Rash 56.27 10.70 274 56180 437197 50111473
Paradoxical drug reaction 55.50 10.70 40 56414 3607 50545063
Inhibitory drug interaction 54.76 10.70 33 56421 2200 50546470
Abdominal discomfort 53.81 10.70 111 56343 231530 50317140
Swelling 51.24 10.70 91 56363 200781 50347889
Infection susceptibility increased 50.34 10.70 33 56421 2551 50546119
Chronic kidney disease 47.87 10.70 124 56330 39647 50509023
Acute motor-sensory axonal neuropathy 46.85 10.70 16 56438 272 50548398
Malignant catatonia 45.11 10.70 13 56441 122 50548548
Therapeutic product effect decreased 44.16 10.70 52 56402 135998 50412672
Helicobacter infection 43.72 10.70 3 56451 49699 50498971
Myocardial infarction 43.71 10.70 206 56248 88821 50459849
Discomfort 41.36 10.70 36 56418 108344 50440326
Intestinal angioedema 41.19 10.70 18 56436 608 50548062
Malignant hypertension 40.34 10.70 21 56433 1053 50547617
Glucose tolerance impaired 39.75 10.70 38 56416 5080 50543590
Neutropenia 39.58 10.70 65 56389 147900 50400770
Unresponsive to stimuli 39.50 10.70 98 56356 30511 50518159
Duodenal ulcer perforation 39.41 10.70 3 56451 45608 50503062
Asthma 39.06 10.70 200 56254 89137 50459533
Nodal rhythm 37.75 10.70 23 56431 1564 50547106
Skin induration 37.75 10.70 29 56425 2882 50545788
Arthralgia 37.68 10.70 311 56143 438391 50110279
Peritonitis bacterial 36.94 10.70 35 56419 4626 50544044
Lower respiratory tract infection 35.87 10.70 32 56422 95169 50453501
Accidental exposure to product by child 35.28 10.70 19 56435 1021 50547649
Toxicity to various agents 35.14 10.70 377 56077 212122 50336548
Somnolence 34.58 10.70 293 56161 154692 50393978
Cardiac arrest 34.31 10.70 184 56270 83467 50465203
Withdrawal syndrome 33.70 10.70 66 56388 17524 50531146
Product substitution issue 33.56 10.70 58 56396 13999 50534671
Hypothermia 33.28 10.70 53 56401 11963 50536707
Left ventricular hypertrophy 32.12 10.70 33 56421 4812 50543858
Coronary artery disease 32.05 10.70 89 56365 29637 50519033
Impaired quality of life 31.00 10.70 36 56418 6020 50542650
Nasopharyngitis 30.82 10.70 111 56343 192816 50355854
Abortion spontaneous 30.45 10.70 5 56449 41767 50506903
Febrile neutropenia 29.93 10.70 39 56415 97628 50451042
Respiratory arrest 29.59 10.70 87 56367 29922 50518748
Malignant neoplasm progression 29.33 10.70 20 56434 68104 50480566
Infection 29.32 10.70 97 56357 172857 50375813
C-reactive protein increased 29.31 10.70 19 56435 66455 50482215
Medical device site pain 29.23 10.70 10 56444 171 50548499
Contraindicated product administered 28.50 10.70 79 56375 148879 50399791
Lethargy 28.49 10.70 120 56334 49312 50499358
Impaired healing 28.08 10.70 22 56432 69764 50478906
Skin hypertrophy 27.95 10.70 25 56429 3070 50545600
Drug ineffective 27.69 10.70 700 55754 818633 49730037
Medication error 27.69 10.70 96 56358 36008 50512662
Anti-neutrophil cytoplasmic antibody positive vasculitis 27.66 10.70 22 56432 2300 50546370
Anuria 27.64 10.70 47 56407 11197 50537473
Cardio-respiratory arrest 27.39 10.70 126 56328 53766 50494904
Condition aggravated 27.12 10.70 207 56247 296851 50251819
Sinusitis 26.02 10.70 100 56354 170458 50378212
Anaesthesia 25.82 10.70 11 56443 349 50548321
Back pain 25.81 10.70 366 56088 219664 50329006
Gastrointestinal disorder 25.71 10.70 41 56413 94415 50454255
Drug ineffective for unapproved indication 25.24 10.70 66 56388 21215 50527455
Miosis 25.03 10.70 33 56421 6277 50542393
Extrapyramidal disorder 24.81 10.70 46 56408 11724 50536946
Sleep disorder due to general medical condition, insomnia type 24.71 10.70 3 56451 31444 50517226
Hyperlipidaemia 24.71 10.70 58 56396 17432 50531238
Basal ganglion degeneration 24.49 10.70 11 56443 397 50548273
Retrograde amnesia 24.41 10.70 11 56443 400 50548270
Acute myocardial infarction 24.36 10.70 80 56374 29193 50519477
Urinary incontinence 24.29 10.70 78 56376 28130 50520540
Tissue infiltration 24.23 10.70 12 56442 541 50548129
Interstitial lung disease 23.72 10.70 15 56439 53161 50495509
Encephalomalacia 23.48 10.70 11 56443 438 50548232
Agitation 22.96 10.70 119 56335 53265 50495405
Apnoea 22.50 10.70 33 56421 6933 50541737
Blister 22.39 10.70 38 56416 85380 50463290
Irritable bowel syndrome 22.28 10.70 15 56439 51426 50497244
Blood aldosterone increased 22.17 10.70 8 56446 161 50548509
Injection site erythema 21.87 10.70 31 56423 74905 50473765
Accidental overdose 21.57 10.70 59 56395 19474 50529196
Primary hyperaldosteronism 21.24 10.70 6 56448 52 50548618
Hypertensive emergency 21.21 10.70 16 56438 1547 50547123
Pyrexia 21.10 10.70 298 56156 379905 50168765
Respiratory moniliasis 21.10 10.70 8 56446 186 50548484
Pulse absent 20.42 10.70 26 56428 4780 50543890
Norepinephrine increased 20.21 10.70 6 56448 63 50548607
Drug dependence 20.17 10.70 58 56396 19701 50528969
Implant site extravasation 19.91 10.70 10 56444 465 50548205
Suspected suicide 19.70 10.70 27 56427 5330 50543340
Leukopenia 19.64 10.70 28 56426 67500 50481170
Osteonecrosis of jaw 19.50 10.70 6 56448 32520 50516150
Skin disorder 19.39 10.70 65 56389 23965 50524705
Atrioventricular block second degree 19.33 10.70 22 56432 3599 50545071
Medical device site discharge 19.16 10.70 5 56449 31 50548639
Purpura 18.76 10.70 37 56417 9874 50538796
Implant site infection 18.68 10.70 12 56442 896 50547774
Application site pain 18.48 10.70 22 56432 3776 50544894
Application site discolouration 18.18 10.70 11 56443 739 50547931
Poor quality sleep 18.10 10.70 50 56404 16596 50532074
Renin decreased 17.96 10.70 6 56448 95 50548575
Gastrointestinal tract mucosal pigmentation 17.96 10.70 10 56444 574 50548096
Erythema 17.73 10.70 245 56209 146169 50402501
Cerebral ischaemia 17.67 10.70 27 56427 5881 50542789
Hypertrichosis 17.53 10.70 12 56442 997 50547673
Renal transplant failure 17.51 10.70 10 56444 603 50548067
Diarrhoea 17.40 10.70 512 55942 587964 49960706
Anhedonia 17.36 10.70 35 56419 9489 50539181
Bone density decreased 17.06 10.70 38 56416 11037 50537633
Pernicious anaemia 16.99 10.70 10 56444 638 50548032
Uterine enlargement 16.93 10.70 12 56442 1054 50547616
Hyperlactacidaemia 16.91 10.70 17 56437 2416 50546254
Focal segmental glomerulosclerosis 16.61 10.70 13 56441 1328 50547342
Renal failure 16.59 10.70 187 56267 106446 50442224
Off label use 16.57 10.70 403 56051 474023 50074647
Application site vesicles 16.49 10.70 13 56441 1342 50547328
Posterior reversible encephalopathy syndrome 16.39 10.70 45 56409 14883 50533787
Device infusion issue 16.39 10.70 13 56441 1354 50547316
White blood cell count decreased 16.18 10.70 71 56383 116651 50432019
Application site papules 16.17 10.70 5 56449 61 50548609
Inguinal hernia 15.84 10.70 14 56440 1692 50546978
Blood pressure abnormal 15.60 10.70 40 56414 12707 50535963
Tachyphylaxis 15.47 10.70 7 56447 257 50548413
Medical device site erythema 15.44 10.70 4 56450 24 50548646
Cardiac hypertrophy 15.40 10.70 11 56443 978 50547692
Gamma-glutamyltransferase increased 15.19 10.70 7 56447 29616 50519054
Human ehrlichiosis 14.99 10.70 6 56448 162 50548508
Hepatotoxicity 14.65 10.70 6 56448 27220 50521450
Tremor 14.62 10.70 194 56260 114709 50433961
Seizure 14.57 10.70 198 56256 117676 50430994
Neutrophil count decreased 14.49 10.70 18 56436 46008 50502662
Arthritis 14.43 10.70 49 56405 86672 50461998
Sinus arrhythmia 14.27 10.70 12 56442 1357 50547313
Mobility decreased 14.12 10.70 44 56410 79904 50468766
Dialysis 14.11 10.70 32 56422 9406 50539264
Disease progression 14.10 10.70 57 56397 95809 50452861
Hyperaesthesia 13.68 10.70 29 56425 8144 50540526
Patent ductus arteriosus 13.67 10.70 19 56435 3801 50544869
Systolic dysfunction 13.51 10.70 12 56442 1460 50547210
Dry mouth 13.47 10.70 108 56346 56070 50492600
SJS-TEN overlap 13.40 10.70 6 56448 215 50548455
Trichoglossia 13.37 10.70 6 56448 216 50548454
Neoplasm progression 13.31 10.70 8 56446 29149 50519521
Page kidney 13.25 10.70 3 56451 9 50548661
Psoriatic arthropathy 13.19 10.70 20 56434 47012 50501658
Coma scale abnormal 13.15 10.70 21 56433 4750 50543920
Intentional product use issue 13.12 10.70 43 56411 76875 50471795
Delirium 13.02 10.70 80 56374 38112 50510558
Hip arthroplasty 13.00 10.70 9 56445 30420 50518250
Blood glucose increased 12.92 10.70 129 56325 71195 50477475
End stage renal disease 12.82 10.70 23 56431 5714 50542956
Aggression 12.74 10.70 52 56402 21064 50527606
Product quality issue 12.73 10.70 68 56386 30790 50517880
Kidney fibrosis 12.72 10.70 12 56442 1577 50547093
Pulmonary renal syndrome 12.72 10.70 7 56447 393 50548277
Injection site abscess 12.63 10.70 10 56444 1039 50547631
Klebsiella infection 12.59 10.70 26 56428 7168 50541502
Injection site pruritus 12.52 10.70 16 56438 40395 50508275
Normochromic normocytic anaemia 12.47 10.70 19 56435 4127 50544543
Hypertensive heart disease 12.47 10.70 14 56440 2256 50546414
Fibrosis 12.46 10.70 18 56436 3729 50544941
Hypernatraemia 12.45 10.70 24 56430 6297 50542373
Spinal pain 12.30 10.70 33 56421 10770 50537900
Hepatic function abnormal 12.28 10.70 11 56443 32670 50516000
Vascular stenosis 12.19 10.70 6 56448 267 50548403
Pain in jaw 12.13 10.70 15 56439 38413 50510257
Drug detoxification 12.12 10.70 5 56449 146 50548524
Skin fibrosis 12.12 10.70 9 56445 850 50547820
Loss of personal independence in daily activities 12.05 10.70 39 56415 70011 50478659
Bone marrow failure 12.03 10.70 8 56446 27616 50521054
Respiratory depression 12.01 10.70 35 56419 11975 50536695
Musculoskeletal stiffness 11.95 10.70 89 56365 128392 50420278
Fanconi syndrome 11.93 10.70 10 56444 1126 50547544
Left atrial dilatation 11.85 10.70 12 56442 1720 50546950
Injection site pain 11.76 10.70 74 56380 110950 50437720
Emotional distress 11.71 10.70 63 56391 28600 50520070
Device expulsion 11.70 10.70 9 56445 28813 50519857
Exposure via ingestion 11.65 10.70 15 56439 2788 50545882
Drug abuser 11.54 10.70 15 56439 2813 50545857
Parosmia 11.51 10.70 19 56435 4417 50544253
Alanine aminotransferase increased 11.50 10.70 55 56399 88304 50460366
Product use issue 11.44 10.70 109 56345 149366 50399304
Enthesopathy 11.44 10.70 25 56429 7168 50541502
Femur fracture 11.43 10.70 15 56439 37449 50511221
Melaena 11.41 10.70 8 56446 26856 50521814
Drug reaction with eosinophilia and systemic symptoms 11.38 10.70 9 56445 28415 50520255
Implant site haematoma 11.35 10.70 4 56450 75 50548595
Knee arthroplasty 11.30 10.70 14 56440 35832 50512838
Daydreaming 11.24 10.70 6 56448 317 50548353
Ill-defined disorder 11.19 10.70 28 56426 54626 50494044
COVID-19 11.12 10.70 22 56432 46640 50502030
Application site haematoma 11.06 10.70 3 56451 22 50548648
Glomerulonephritis 11.03 10.70 11 56443 1548 50547122
Enterococcal infection 11.00 10.70 24 56430 6874 50541796
Rhinorrhoea 10.90 10.70 26 56428 51557 50497113
Psychogenic seizure 10.88 10.70 11 56443 1574 50547096
Medical device site swelling 10.83 10.70 3 56451 24 50548646
Drug dependence, antepartum 10.73 10.70 3 56451 25 50548645
Myasthenic syndrome 10.72 10.70 5 56449 197 50548473

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 218.54 10.98 406 37764 89840 29446517
Drug withdrawal syndrome 166.57 10.98 157 38013 17827 29518530
Withdrawal hypertension 134.05 10.98 33 38137 130 29536227
Aggression 124.75 10.98 189 37981 35352 29501005
Bradycardia 122.38 10.98 265 37905 65364 29470993
Hypertension 90.53 10.98 343 37827 116271 29420086
Respiratory depression 90.36 10.98 99 38071 13424 29522933
Hypertensive crisis 89.38 10.98 77 38093 7771 29528586
Drug dependence 77.05 10.98 114 38056 20867 29515490
Oppositional defiant disorder 76.58 10.98 28 38142 503 29535854
Victim of child abuse 73.87 10.98 31 38139 814 29535543
Decreased eye contact 71.53 10.98 26 38144 459 29535898
Application site rash 70.06 10.98 29 38141 735 29535622
Choreoathetosis 68.26 10.98 31 38139 989 29535368
Blood pressure inadequately controlled 65.66 10.98 40 38130 2346 29534011
Febrile neutropenia 61.74 10.98 34 38136 112206 29424151
Sedation 60.24 10.98 92 38078 17313 29519044
Anxiety 59.62 10.98 243 37927 85122 29451235
Miosis 59.44 10.98 62 38108 7947 29528410
Withdrawal syndrome 59.19 10.98 72 38098 10920 29525437
Sinus bradycardia 56.08 10.98 72 38098 11531 29524826
Product substitution issue 54.20 10.98 63 38107 9109 29527248
Blood pressure increased 53.85 10.98 213 37957 73590 29462767
Cardiac failure congestive 53.47 10.98 218 37952 76363 29459994
Hypotension 51.40 10.98 427 37743 193927 29342430
Crying 50.06 10.98 47 38123 5304 29531053
Trismus 48.52 10.98 33 38137 2340 29534017
Dystonia 47.91 10.98 61 38109 9688 29526669
Bruxism 47.28 10.98 28 38142 1559 29534798
Homicidal ideation 46.68 10.98 33 38137 2491 29533866
Accidental exposure to product by child 45.95 10.98 26 38144 1328 29535029
Agitation 45.74 10.98 158 38012 51146 29485211
Product adhesion issue 43.95 10.98 26 38144 1445 29534912
Pyrexia 42.50 10.98 209 37961 287413 29248944
Hypertensive emergency 42.42 10.98 21 38149 815 29535542
Somnolence 41.92 10.98 235 37935 93720 29442637
Nephrogenic systemic fibrosis 41.51 10.98 37 38133 3905 29532452
Cerebrovascular accident 40.92 10.98 202 37968 76709 29459648
Mental status changes 40.70 10.98 118 38052 34809 29501548
Suicidal ideation 39.22 10.98 116 38054 34600 29501757
Lethargy 39.11 10.98 122 38048 37458 29498899
Overweight 38.99 10.98 24 38146 1434 29534923
Interstitial lung disease 38.85 10.98 13 38157 57705 29478652
Irritability 38.45 10.98 87 38083 22065 29514292
Neutropenia 38.02 10.98 70 38100 131641 29404716
Malignant catatonia 36.38 10.98 13 38157 218 29536139
Catatonia 35.71 10.98 36 38134 4432 29531925
Obesity 35.35 10.98 53 38117 9810 29526547
Psychomotor hyperactivity 35.12 10.98 48 38122 8165 29528192
Dyskinesia 35.06 10.98 79 38091 19982 29516375
Pneumonia 34.98 10.98 256 37914 319916 29216441
Peritonitis bacterial 34.78 10.98 40 38130 5716 29530641
Epidural lipomatosis 33.55 10.98 17 38153 694 29535663
Thrombocytopenia 32.74 10.98 79 38091 134744 29401613
Hepatic function abnormal 31.89 10.98 6 38164 39253 29497104
Respiratory arrest 31.77 10.98 89 38081 25744 29510613
Cardiac arrest 31.72 10.98 204 37966 85387 29450970
Tic 31.66 10.98 23 38147 1812 29534545
Hyperaesthesia 31.55 10.98 30 38140 3439 29532918
Application site pruritus 31.29 10.98 20 38150 1277 29535080
Pancytopenia 31.00 10.98 37 38133 83131 29453226
Blood prolactin increased 30.58 10.98 21 38149 1513 29534844
Hypotonia 30.51 10.98 41 38129 6861 29529496
Neuroleptic malignant syndrome 29.80 10.98 65 38105 16083 29520274
Device failure 29.73 10.98 23 38147 1993 29534364
Aplastic anaemia 29.29 10.98 42 38128 7468 29528889
Application site erythema 28.91 10.98 23 38147 2076 29534281
Emotional distress 28.03 10.98 58 38112 13837 29522520
Suspected suicide 27.84 10.98 30 38140 3990 29532367
Unresponsive to stimuli 27.47 10.98 83 38087 25043 29511314
Malignant neoplasm progression 27.37 10.98 33 38137 73826 29462531
Affect lability 26.44 10.98 27 38143 3375 29532982
Accelerated hypertension 25.18 10.98 10 38160 227 29536130
Toxicity to various agents 24.74 10.98 337 37833 173324 29363033
Inadequate analgesia 24.23 10.98 23 38147 2631 29533726
Serotonin syndrome 24.21 10.98 63 38107 17449 29518908
Application site irritation 23.77 10.98 13 38157 621 29535736
Juvenile idiopathic arthritis 22.98 10.98 17 38153 1377 29534980
Poisoning 22.91 10.98 44 38126 9949 29526408
Injury 22.81 10.98 65 38105 18981 29517376
Autonomic nervous system imbalance 22.47 10.98 21 38149 2355 29534002
Drug tolerance 22.26 10.98 20 38150 2133 29534224
Product prescribing error 22.16 10.98 62 38108 17914 29518443
Tardive dyskinesia 21.38 10.98 30 38140 5228 29531129
Corneal reflex decreased 21.04 10.98 8 38162 161 29536196
Hyperkinesia 20.92 10.98 17 38153 1582 29534775
Galactorrhoea 20.30 10.98 10 38160 384 29535973
Anger 20.28 10.98 44 38126 10846 29525511
Insomnia 20.26 10.98 189 37981 88572 29447785
Kidney transplant rejection 20.09 10.98 34 38136 6971 29529386
Pain 19.84 10.98 321 37849 171111 29365246
Coordination abnormal 19.70 10.98 34 38136 7080 29529277
Overdose 19.25 10.98 172 37998 79647 29456710
Accidental overdose 19.12 10.98 58 38112 17535 29518822
Labile hypertension 19.10 10.98 6 38164 66 29536291
Axillary pain 19.02 10.98 9 38161 316 29536041
Medical device site pain 18.94 10.98 6 38164 68 29536289
Fibrosis 18.84 10.98 19 38151 2340 29534017
Rheumatoid arthritis 18.76 10.98 9 38161 32143 29504214
Product administered to patient of inappropriate age 18.71 10.98 20 38150 2635 29533722
Tourette's disorder 18.63 10.98 6 38164 72 29536285
Platelet count decreased 18.47 10.98 71 38099 104601 29431756
Speech disorder 18.04 10.98 69 38101 23447 29512910
Metabolic alkalosis 18.01 10.98 14 38156 1222 29535135
Attention deficit hyperactivity disorder 17.97 10.98 18 38152 2199 29534158
Mood altered 17.72 10.98 35 38135 8076 29528281
Diarrhoea 17.61 10.98 313 37857 332385 29203972
Drug screen positive 17.45 10.98 23 38147 3778 29532579
Implant site extravasation 17.41 10.98 9 38161 383 29535974
Accidental poisoning 17.03 10.98 10 38160 548 29535809
Natural killer cell count decreased 16.96 10.98 3 38167 0 29536357
Anhedonia 16.87 10.98 32 38138 7168 29529189
Poor quality sleep 16.76 10.98 32 38138 7201 29529156
Loss of consciousness 16.55 10.98 157 38013 73899 29462458
Brief psychotic disorder with marked stressors 16.46 10.98 7 38163 190 29536167
Reaction to excipient 16.36 10.98 9 38161 435 29535922
Abnormal behaviour 16.24 10.98 66 38104 23061 29513296
Device infusion issue 16.18 10.98 10 38160 602 29535755
Respiratory rate decreased 16.15 10.98 16 38154 1929 29534428
Device power source issue 16.03 10.98 8 38162 316 29536041
Streptococcal infection 15.91 10.98 24 38146 4464 29531893
Oromandibular dystonia 15.85 10.98 9 38161 463 29535894
Transcription medication error 15.72 10.98 6 38164 122 29536235
Neutrophil count decreased 15.57 10.98 20 38150 43547 29492810
General physical health deterioration 15.55 10.98 74 38096 102783 29433574
Autoimmune enteropathy 15.48 10.98 4 38166 20 29536337
Cardio-respiratory arrest 15.41 10.98 115 38055 50486 29485871
Mast cell degranulation present 15.30 10.98 5 38165 63 29536294
Drooling 14.99 10.98 19 38151 3002 29533355
Double inlet left ventricle 14.86 10.98 4 38166 24 29536333
Myocardial infarction 14.85 10.98 212 37958 110084 29426273
Gastrointestinal tract mucosal pigmentation 14.77 10.98 8 38162 375 29535982
Renal transplant 14.73 10.98 14 38156 1604 29534753
Product compounding quality issue 14.72 10.98 4 38166 25 29536332
Contraindicated product administered 14.40 10.98 3 38167 18263 29518094
Metastases to eye 14.38 10.98 5 38165 77 29536280
Labelled drug-drug interaction issue 14.32 10.98 6 38164 157 29536200
End stage renal disease 14.31 10.98 31 38139 7633 29528724
Skin tightness 14.21 10.98 15 38155 1949 29534408
Post transplant distal limb syndrome 13.92 10.98 7 38163 281 29536076
Hypoxic-ischaemic encephalopathy 13.92 10.98 22 38148 4262 29532095
Drug withdrawal maintenance therapy 13.87 10.98 5 38165 86 29536271
Inflammation 13.82 10.98 6 38164 22722 29513635
Sprue-like enteropathy 13.73 10.98 8 38162 432 29535925
Toxic epidermal necrolysis 13.71 10.98 53 38117 18100 29518257
Skin induration 13.65 10.98 15 38155 2039 29534318
Incision site pain 13.58 10.98 14 38156 1769 29534588
Disease progression 13.54 10.98 57 38113 81859 29454498
Univentricular heart 13.45 10.98 4 38166 36 29536321
Skin hypertrophy 13.36 10.98 16 38154 2387 29533970
Impaired gastric emptying 13.21 10.98 18 38152 3052 29533305
Lower respiratory tract infection 13.20 10.98 9 38161 26493 29509864
Therapeutic response decreased 13.19 10.98 65 38105 24646 29511711
Muscle spasticity 13.08 10.98 23 38147 4860 29531497
Hydrocele male infected 13.08 10.98 4 38166 40 29536317
Infection 12.94 10.98 53 38117 76698 29459659
Atrioventricular block first degree 12.91 10.98 24 38146 5295 29531062
Harlequin syndrome 12.82 10.98 3 38167 9 29536348
Pneumocystis jirovecii pneumonia 12.73 10.98 3 38167 16776 29519581
Cardiomyopathy 12.69 10.98 45 38125 14742 29521615
Productive cough 12.63 10.98 13 38157 31246 29505111
Impulsive behaviour 12.59 10.98 14 38156 1929 29534428
Hyperhidrosis 12.57 10.98 133 38037 64407 29471950
Product prescribing issue 12.38 10.98 11 38159 1156 29535201
Child abuse 12.31 10.98 6 38164 225 29536132
Electrocardiogram PR prolongation 12.24 10.98 9 38161 722 29535635
Rash 12.22 10.98 172 37998 189647 29346710
Cancer pain 12.03 10.98 15 38155 2332 29534025
Nervousness 12.03 10.98 37 38133 11269 29525088
White blood cell count decreased 12.00 10.98 61 38109 83301 29453056
Cardiac failure 12.00 10.98 57 38113 79230 29457127
Product preparation issue 11.88 10.98 6 38164 243 29536114
Nephropathy 11.85 10.98 23 38147 5240 29531117
Tremor 11.82 10.98 146 38024 73392 29462965
Chronic kidney disease 11.79 10.98 84 38086 36332 29500025
Paradoxical drug reaction 11.69 10.98 16 38154 2725 29533632
Infusion site mass 11.66 10.98 6 38164 253 29536104
C-reactive protein increased 11.48 10.98 25 38145 44238 29492119
Cytomegalovirus infection 11.41 10.98 8 38162 23207 29513150
Intentional product misuse 11.25 10.98 80 38090 34581 29501776
Depression 11.19 10.98 163 38007 84984 29451373
Sepsis 11.16 10.98 124 38046 142558 29393799
Lymphocele 11.14 10.98 11 38159 1321 29535036
Rash maculo-papular 11.12 10.98 9 38161 24280 29512077
Brain injury 11.11 10.98 23 38147 5489 29530868
Disseminated intravascular coagulation 11.04 10.98 6 38164 19974 29516383

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 530.80 10.31 965 77356 223449 64196962
Temperature regulation disorder 318.70 10.31 137 78184 4074 64416337
Drug withdrawal syndrome 282.20 10.31 262 78059 31029 64389382
Bradycardia 238.85 10.31 476 77845 117743 64302668
Coeliac disease 234.28 10.31 133 78188 7279 64413132
Hypertensive crisis 227.80 10.31 184 78137 18064 64402347
Food allergy 224.52 10.31 132 78189 7719 64412692
Hypertension 179.98 10.31 706 77615 258555 64161856
Withdrawal hypertension 177.78 10.31 47 78274 280 64420131
Cardiac failure congestive 177.45 10.31 449 77872 130131 64290280
Bursitis 169.25 10.31 167 78154 21318 64399093
Immunodeficiency 153.11 10.31 139 78182 15985 64404426
Mental status changes 153.01 10.31 270 78051 60892 64359519
Sinus bradycardia 137.54 10.31 154 78167 22739 64397672
Aggression 123.34 10.31 210 78111 46022 64374389
Hyperhidrosis 116.42 10.31 375 77946 124545 64295866
Overdose 115.02 10.31 440 77881 159126 64261285
Cerebrovascular accident 110.57 10.31 393 77928 137190 64283221
Poisoning 103.06 10.31 130 78191 21749 64398662
Sedation 90.99 10.31 173 78148 41289 64379122
Hypotension 90.73 10.31 780 77541 380194 64040217
Respiratory depression 89.96 10.31 126 78195 23317 64397094
Blood pressure inadequately controlled 88.56 10.31 64 78257 5320 64415091
Synovitis 88.07 10.31 9 78312 99081 64321330
Miosis 87.96 10.31 94 78227 13172 64407239
Accidental exposure to product by child 85.08 10.31 47 78274 2438 64417973
Withdrawal syndrome 80.98 10.31 120 78201 23372 64397039
Oppositional defiant disorder 80.66 10.31 28 78293 458 64419953
Malignant catatonia 79.49 10.31 26 78295 351 64420060
Drug dependence 79.36 10.31 144 78177 33168 64387243
Neutropenia 77.15 10.31 107 78214 239517 64180894
Febrile neutropenia 76.60 10.31 69 78252 187588 64232823
Victim of child abuse 74.78 10.31 31 78290 840 64419571
Joint swelling 73.60 10.31 92 78229 215290 64205121
Toxicity to various agents 71.74 10.31 715 77606 362798 64057613
Cardiac arrest 71.00 10.31 372 77949 153692 64266719
Neovascularisation 70.90 10.31 32 78289 1071 64419340
Nephrogenic systemic fibrosis 68.46 10.31 57 78264 5835 64414576
Respiratory arrest 67.56 10.31 178 78143 52807 64367604
Hypertensive encephalopathy 67.17 10.31 29 78292 871 64419540
Somnolence 65.77 10.31 448 77873 203197 64217214
Lethargy 64.95 10.31 215 78106 72379 64348032
Body tinea 63.04 10.31 31 78290 1262 64419149
Infusion related reaction 63.00 10.31 64 78257 164403 64256008
Paradoxical drug reaction 62.53 10.31 55 78266 6065 64414346
Rash erythematous 61.62 10.31 163 78158 48470 64371941
Decreased eye contact 61.56 10.31 26 78295 739 64419672
Choreoathetosis 59.74 10.31 31 78290 1416 64418995
Interstitial lung disease 59.66 10.31 22 78299 97710 64322701
Fluid retention 59.20 10.31 183 78138 59423 64360988
Arthropathy 58.95 10.31 37 78284 120930 64299481
Blood pressure increased 58.34 10.31 384 77937 172168 64248243
Drug intolerance 57.48 10.31 87 78234 187905 64232506
Agitation 57.42 10.31 236 78085 88131 64332280
Alopecia 57.40 10.31 70 78251 165620 64254791
Hypertensive emergency 56.63 10.31 35 78286 2241 64418170
Rash 56.10 10.31 327 77994 458222 63962189
Myocardial infarction 54.84 10.31 367 77954 165454 64254957
Malignant neoplasm progression 54.35 10.31 35 78286 112836 64307575
Pyrexia 54.11 10.31 427 77894 558217 63862194
Upper respiratory tract infection 52.61 10.31 201 78120 72584 64347827
Unresponsive to stimuli 50.31 10.31 155 78166 50238 64370173
Anxiety 50.27 10.31 419 77902 202230 64218181
Homicidal ideation 49.69 10.31 37 78284 3220 64417191
Infection susceptibility increased 48.51 10.31 34 78287 2692 64417719
Medical device site pain 47.13 10.31 16 78305 244 64420167
Arthralgia 46.61 10.31 330 77991 441930 63978481
Suspected suicide 46.55 10.31 55 78266 8599 64411812
Glossodynia 45.96 10.31 11 78310 64685 64355726
Pericarditis 45.67 10.31 10 78311 62506 64357905
Application site pruritus 44.82 10.31 36 78285 3503 64416908
Trismus 44.09 10.31 41 78280 4860 64415551
Application site irritation 43.75 10.31 26 78295 1550 64418861
Application site rash 43.49 10.31 28 78293 1926 64418485
Diarrhoea 42.94 10.31 619 77702 722085 63698326
Cardio-respiratory arrest 42.85 10.31 234 78087 98159 64322252
Medication error 42.05 10.31 145 78176 49821 64370590
Accidental overdose 41.02 10.31 111 78210 33446 64386965
Lower respiratory tract infection 40.77 10.31 33 78288 94581 64325830
Irritability 40.44 10.31 117 78204 36629 64383782
Hepatic function abnormal 40.06 10.31 14 78307 64299 64356112
Acute motor-sensory axonal neuropathy 39.94 10.31 16 78305 396 64420015
Inhibitory drug interaction 39.90 10.31 34 78287 3593 64416818
Peritonitis bacterial 39.86 10.31 52 78269 8991 64411420
Systemic lupus erythematosus 38.84 10.31 23 78298 77589 64342822
Apnoea 38.48 10.31 55 78266 10367 64410044
Maternal exposure during pregnancy 38.22 10.31 36 78285 95848 64324563
Poor quality sleep 37.83 10.31 76 78245 18875 64401536
Crying 37.07 10.31 78 78243 20012 64400399
Obesity 36.98 10.31 79 78242 20483 64399928
Condition aggravated 36.76 10.31 283 78038 372143 64048268
Hyperaesthesia 35.73 10.31 52 78269 9962 64410449
Catatonia 35.44 10.31 45 78276 7575 64412836
Constipation 35.43 10.31 430 77891 228907 64191504
Helicobacter infection 35.37 10.31 3 78318 38359 64382052
Nasopharyngitis 35.28 10.31 121 78200 195952 64224459
Thrombocytopenia 35.15 10.31 146 78175 223655 64196756
Intestinal angioedema 34.85 10.31 18 78303 814 64419597
Glucose tolerance impaired 34.74 10.31 41 78280 6402 64414009
Implant site extravasation 33.75 10.31 17 78304 729 64419682
Product substitution issue 33.72 10.31 70 78251 17791 64402620
Infection 33.32 10.31 114 78207 184766 64235645
Drug ineffective for unapproved indication 33.18 10.31 98 78223 31035 64389376
Gastrointestinal tract mucosal pigmentation 33.02 10.31 18 78303 909 64419502
Malignant hypertension 32.84 10.31 21 78300 1427 64418984
Wound 32.54 10.31 27 78294 76450 64343961
Coronary artery disease 32.11 10.31 152 78169 60281 64360130
Left ventricular hypertrophy 31.96 10.31 48 78273 9458 64410953
Chronic kidney disease 31.74 10.31 147 78174 57772 64362639
Epidural lipomatosis 31.16 10.31 17 78304 860 64419551
Dystonia 31.11 10.31 70 78251 18795 64401616
C-reactive protein increased 30.89 10.31 42 78279 94867 64325544
Neutrophil count decreased 30.74 10.31 29 78292 77167 64343244
Application site erythema 30.68 10.31 33 78288 4656 64415755
Swelling 30.10 10.31 97 78224 160121 64260290
Bruxism 30.09 10.31 29 78292 3595 64416816
Exposure during pregnancy 28.85 10.31 31 78290 77644 64342767
Suicidal ideation 28.79 10.31 158 78163 66384 64354027
Duodenal ulcer perforation 28.65 10.31 4 78317 34621 64385790
Skin hypertrophy 28.11 10.31 31 78290 4498 64415913
Osteonecrosis of jaw 27.84 10.31 7 78314 39818 64380593
Tic 27.69 10.31 24 78297 2595 64417816
Dyskinesia 27.01 10.31 107 78214 39281 64381130
Device infusion issue 26.88 10.31 20 78301 1738 64418673
Product compounding quality issue 26.72 10.31 7 78314 40 64420371
White blood cell count decreased 26.66 10.31 100 78221 157737 64262674
Skin induration 26.65 10.31 29 78292 4146 64416265
Emotional distress 26.42 10.31 100 78221 35938 64384473
Therapeutic product effect decreased 25.98 10.31 64 78257 115287 64305124
Nodal rhythm 25.77 10.31 24 78297 2850 64417561
Drug screen positive 25.34 10.31 33 78288 5696 64414715
Anti-neutrophil cytoplasmic antibody positive vasculitis 25.33 10.31 24 78297 2912 64417499
Posterior reversible encephalopathy syndrome 25.19 10.31 73 78248 22873 64397538
Kidney transplant rejection 25.08 10.31 43 78278 9468 64410943
Anhedonia 25.04 10.31 53 78268 13653 64406758
Product adhesion issue 24.93 10.31 22 78299 2437 64417974
Pneumonia 24.81 10.31 505 77816 559071 63861340
Medical device site discharge 24.69 10.31 7 78314 56 64420355
Overweight 24.49 10.31 25 78296 3321 64417090
Anger 24.40 10.31 57 78264 15684 64404727
Psoriatic arthropathy 24.36 10.31 11 78310 43270 64377141
Sinusitis 24.29 10.31 93 78228 145835 64274576
Bone marrow failure 24.29 10.31 14 78307 47938 64372473
Psychomotor hyperactivity 24.26 10.31 54 78267 14397 64406014
Arthritis 23.52 10.31 41 78280 83773 64336638
Blood prolactin increased 23.39 10.31 25 78296 3503 64416908
Aplastic anaemia 23.35 10.31 52 78269 13868 64406543
Pneumocystis jirovecii pneumonia 23.32 10.31 3 78318 27631 64392780
Neuroleptic malignant syndrome 23.21 10.31 75 78246 24921 64395490
Asthma 23.10 10.31 196 78125 95029 64325382
Application site discolouration 22.97 10.31 13 78308 707 64419704
Oromandibular dystonia 22.61 10.31 14 78307 899 64419512
Impaired healing 22.61 10.31 24 78297 60449 64359962
Disease progression 22.50 10.31 92 78229 141588 64278823
Tremor 22.47 10.31 277 78044 147953 64272458
Impaired quality of life 22.22 10.31 33 78288 6438 64413973
Accelerated hypertension 22.09 10.31 12 78309 602 64419809
Sleep disorder due to general medical condition, insomnia type 21.81 10.31 3 78318 26267 64394144
Pancytopenia 21.56 10.31 95 78226 143214 64277197
Intentional product misuse 21.51 10.31 156 78165 72139 64348272
Retrograde amnesia 21.49 10.31 11 78310 488 64419923
Hyperlipidaemia 21.39 10.31 69 78252 22907 64397504
Liver disorder 21.29 10.31 20 78301 53331 64367080
Extrapyramidal disorder 21.26 10.31 62 78259 19490 64400921
Implant site infection 21.18 10.31 17 78304 1652 64418759
Abdominal discomfort 21.18 10.31 132 78189 182190 64238221
Cancer pain 21.17 10.31 26 78295 4231 64416180
Loss of consciousness 21.10 10.31 274 78047 148091 64272320
Rash maculo-papular 20.76 10.31 16 78305 47010 64373401
Fibrosis 20.55 10.31 27 78294 4701 64415710
Basal ganglion degeneration 20.55 10.31 10 78311 398 64420013
Renin decreased 20.48 10.31 7 78314 109 64420302
Affect lability 20.32 10.31 38 78283 8952 64411459
Anaesthesia 20.29 10.31 10 78311 409 64420002
Autonomic nervous system imbalance 20.17 10.31 25 78296 4107 64416304
Leukopenia 19.92 10.31 60 78261 101182 64319229
Acute myocardial infarction 19.92 10.31 149 78172 69569 64350842
Hypothermia 19.74 10.31 61 78260 19795 64400616
Dialysis 19.71 10.31 55 78266 16865 64403546
Tissue infiltration 19.71 10.31 11 78310 582 64419829
Platelet count decreased 19.70 10.31 121 78200 167590 64252821
Injection site erythema 19.54 10.31 35 78286 70765 64349646
Blood aldosterone increased 19.53 10.31 8 78313 210 64420201
Pulmonary fibrosis 19.49 10.31 6 78315 29872 64390539
Atrioventricular block second degree 19.47 10.31 31 78290 6423 64413988
Insomnia 19.45 10.31 343 77978 197493 64222918
Drug tolerance 19.43 10.31 30 78291 6055 64414356
Primary hyperaldosteronism 19.34 10.31 7 78314 130 64420281
Reaction to excipient 19.33 10.31 15 78306 1388 64419023
Infusion site mass 19.26 10.31 13 78308 968 64419443
Device power source issue 19.22 10.31 12 78309 782 64419629
Attention deficit hyperactivity disorder 19.02 10.31 20 78301 2750 64417661
Lymphopenia 18.95 10.31 4 78317 25653 64394758
Hypotonia 18.93 10.31 42 78279 11170 64409241
Acute myeloid leukaemia 18.87 10.31 5 78316 27458 64392953
Norepinephrine increased 18.84 10.31 6 78315 74 64420337
Productive cough 18.61 10.31 38 78283 73165 64347246
Anuria 18.61 10.31 58 78263 18906 64401505
Neutropenic sepsis 18.54 10.31 3 78318 23269 64397142
Urinary incontinence 18.53 10.31 90 78231 36061 64384350
Abnormal behaviour 18.17 10.31 85 78236 33537 64386874
Neoplasm progression 18.00 10.31 14 78307 40950 64379461
Back pain 17.71 10.31 413 77908 249758 64170653
Drug eruption 17.67 10.31 11 78310 36125 64384286
Muscle contracture 17.50 10.31 17 78304 2128 64418283
Irritable bowel syndrome 17.42 10.31 12 78309 37357 64383054
Pernicious anaemia 17.41 10.31 10 78311 559 64419852
Seizure 17.36 10.31 292 78029 166600 64253811
Discomfort 17.34 10.31 46 78275 80832 64339579
Medical device site infection 17.29 10.31 9 78312 414 64419997
Hepatitis 17.14 10.31 18 78303 45564 64374847
Alanine aminotransferase increased 17.02 10.31 99 78222 138932 64281479
Atrioventricular block first degree 16.78 10.31 39 78282 10695 64409716
Bone density decreased 16.49 10.31 37 78284 9915 64410496
Abortion spontaneous 16.49 10.31 5 78316 25138 64395273
Gamma-glutamyltransferase increased 16.26 10.31 21 78300 48489 64371922
Incision site pain 16.19 10.31 18 78303 2636 64417775
Melaena 16.14 10.31 25 78296 53523 64366888
Cytomegalovirus infection 15.99 10.31 13 78308 37186 64383225
Corneal reflex decreased 15.93 10.31 8 78313 341 64420070
Pneumonitis 15.67 10.31 23 78298 50342 64370069
Pulse absent 15.66 10.31 34 78287 8912 64411499
Basal cell carcinoma 15.62 10.31 9 78312 30829 64389582
Mast cell degranulation present 15.60 10.31 5 78316 63 64420348
Product prescribing error 15.42 10.31 84 78237 35185 64385226
Device failure 15.36 10.31 26 78295 5666 64414745
Drooling 15.30 10.31 25 78296 5294 64415117
Drug detoxification 15.16 10.31 7 78314 247 64420164
Injection site abscess 15.16 10.31 13 78308 1385 64419026
Product administered to patient of inappropriate age 15.14 10.31 23 78298 4578 64415833
Intentional product use issue 15.09 10.31 62 78259 95302 64325109
Tardive dyskinesia 15.07 10.31 34 78287 9144 64411267
Hyperkinesia 15.07 10.31 17 78304 2529 64417882
Blood potassium increased 15.02 10.31 67 78254 25913 64394498
Implant site discharge 15.00 10.31 6 78315 148 64420263
Renal injury 14.97 10.31 47 78274 15382 64405029
Depressed level of consciousness 14.95 10.31 158 78163 81278 64339133
Haematochezia 14.80 10.31 37 78284 66336 64354075
Brief psychotic disorder with marked stressors 14.73 10.31 7 78314 264 64420147
Focal segmental glomerulosclerosis 14.67 10.31 18 78303 2926 64417485
Cardiac hypertrophy 14.59 10.31 13 78308 1458 64418953
Renal artery stenosis 14.55 10.31 18 78303 2951 64417460
Uterine enlargement 14.51 10.31 10 78311 771 64419640
Pain in jaw 14.33 10.31 17 78304 40738 64379673
Osteoporosis 14.32 10.31 18 78303 42062 64378349
Brain injury 14.28 10.31 35 78286 9930 64410481
End stage renal disease 14.18 10.31 36 78285 10439 64409972
Drug withdrawal headache 14.17 10.31 5 78316 86 64420325
Inflammation 14.10 10.31 37 78284 65263 64355148
COVID-19 14.00 10.31 37 78284 65103 64355308
Mood altered 13.99 10.31 47 78274 15932 64404479
Device computer issue 13.79 10.31 4 78317 35 64420376
Contraindicated product administered 13.61 10.31 76 78245 107753 64312658
Multiple sclerosis relapse 13.59 10.31 18 78303 41117 64379294
Speech disorder 13.54 10.31 103 78218 48338 64372073
Hypoxic-ischaemic encephalopathy 13.47 10.31 28 78293 7124 64413287
Autoimmune enteropathy 13.41 10.31 4 78317 39 64420372
Agranulocytosis 13.39 10.31 16 78305 38213 64382198
Vascular stenosis 13.38 10.31 8 78313 482 64419929
Renal transplant 13.29 10.31 15 78306 2233 64418178
Osteonecrosis 13.25 10.31 9 78312 28220 64392191
Pulmonary oedema 13.23 10.31 150 78171 78524 64341887
Hypertrichosis 13.12 10.31 11 78310 1137 64419274
Hyperthyroidism 13.09 10.31 3 78318 18176 64402235
Chest discomfort 13.00 10.31 85 78236 116021 64304390
Trichoglossia 12.94 10.31 7 78314 348 64420063
Child abuse 12.94 10.31 6 78315 214 64420197
Respiratory rate decreased 12.77 10.31 21 78300 4470 64415941
Malaise 12.76 10.31 375 77946 395872 64024539
Colitis ulcerative 12.73 10.31 6 78315 23022 64397389
Skin tightness 12.52 10.31 22 78299 4939 64415472
Product quality issue 12.38 10.31 70 78251 29729 64390682
Skin disorder 12.15 10.31 66 78255 27614 64392797
Educational problem 12.10 10.31 7 78314 397 64420014
Rash pruritic 12.04 10.31 33 78288 57371 64363040
Application site papules 12.03 10.31 4 78317 57 64420354
Sinus arrhythmia 11.95 10.31 13 78308 1857 64418554
Dry mouth 11.94 10.31 119 78202 60299 64360112
Coma scale abnormal 11.89 10.31 28 78293 7746 64412665
Respiratory moniliasis 11.83 10.31 6 78315 261 64420150
Labelled drug-drug interaction medication error 11.82 10.31 6 78315 22056 64398355
Gun shot wound 11.76 10.31 10 78311 1054 64419357
Respiratory tract infection 11.72 10.31 17 78304 37390 64383021
Peritoneal dialysis complication 11.72 10.31 14 78307 2214 64418197
Delirium 11.66 10.31 132 78189 69062 64351349
Encephalomalacia 11.54 10.31 10 78311 1081 64419330
Pruritus 11.51 10.31 290 78031 312110 64108301
Cardiac failure 11.48 10.31 104 78217 132269 64288142
Myelodysplastic syndrome 11.41 10.31 10 78311 27569 64392842
Coordination abnormal 11.36 10.31 42 78279 14922 64405489
Right ventricular failure 11.26 10.31 6 78315 21465 64398946
Normochromic normocytic anaemia 11.23 10.31 25 78296 6665 64413746
Femur fracture 11.21 10.31 15 78306 34120 64386291
Prostate cancer 11.19 10.31 5 78316 19790 64400621
Hip arthroplasty 11.15 10.31 6 78315 21345 64399066
Blood creatinine increased 11.13 10.31 229 78092 135553 64284858
Liver injury 11.05 10.31 12 78309 29920 64390491
Peau d'orange 11.01 10.31 6 78315 303 64420108
Gastrointestinal disorder 10.91 10.31 64 78257 89645 64330766
Loss of personal independence in daily activities 10.91 10.31 48 78273 72406 64348005
Accidental poisoning 10.90 10.31 11 78310 1442 64418969
Skin fibrosis 10.86 10.31 11 78310 1448 64418963
Mood swings 10.82 10.31 46 78275 17422 64402989
Left atrial dilatation 10.81 10.31 15 78306 2751 64417660
Treatment noncompliance 10.81 10.31 90 78231 43392 64377019
Medical device site erythema 10.78 10.31 4 78317 80 64420331
Osteoarthritis 10.77 10.31 40 78281 63296 64357115
Medical device site swelling 10.73 10.31 4 78317 81 64420330
Nervousness 10.72 10.31 67 78254 29489 64390922
Autism spectrum disorder 10.72 10.31 9 78312 932 64419479
Pain 10.70 10.31 795 77526 552716 63867695
Hyporesponsive to stimuli 10.64 10.31 12 78309 1785 64418626
Inadequate analgesia 10.51 10.31 18 78303 3960 64416451
Drug dependence, antepartum 10.47 10.31 3 78318 25 64420386
Product preparation issue 10.35 10.31 8 78313 736 64419675
Post transplant distal limb syndrome 10.35 10.31 7 78314 523 64419888

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AC01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
ATC C02LC01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Imidazoline receptor agonists in combination with diuretics
ATC C02LC51 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Imidazoline receptor agonists in combination with diuretics
ATC N02CX02 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Other antimigraine preparations
ATC S01EA04 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000700 Analgesics
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D013565 Sympatholytics
CHEBI has role CHEBI:35569 alpha-adrenergic agonists
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:66991 sympatholytic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Severe pain indication 76948002
Open-angle glaucoma indication 84494001 DOID:1067
Attention deficit hyperactivity disorder indication 406506008
Increased Intraocular Pressure after Ocular Procedure indication
Ocular hypertension off-label use 4210003 DOID:9282
Gilles de la Tourette's syndrome off-label use 5158005 DOID:11119
Pain off-label use 22253000
Diarrhea off-label use 62315008
Opioid withdrawal off-label use 87132004
Menopausal flushing off-label use 198436008
Smoking cessation assistance off-label use 384742004
Nicotine Withdrawal Symptoms off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Tear film insufficiency contraindication 46152009
End stage renal disease contraindication 46177005 DOID:784
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Bradycardia contraindication 48867003
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Blood coagulation disorder contraindication 64779008 DOID:1247
Hypercalcemia contraindication 66931009 DOID:12678
Hypochloremic alkalosis contraindication 70134007
Decreased respiratory function contraindication 80954004
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Perioperative care contraindication 133897009
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Atrioventricular block contraindication 233917008 DOID:0050820
Labor pain contraindication 247412007
Raynaud's phenomenon contraindication 266261006
Syncope contraindication 271594007
Surgical procedure contraindication 387713003
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Inflammatory dermatosis contraindication 703938007
Vagal Reflex Bradycardia contraindication
Severe Cardiopulmonary Disease contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR AGONIST Ki 7.50 CHEMBL CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST EC50 6.70 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST Ki 8.42 CHEMBL CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 6.22 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 6.50 PDSP
Nischarin Membrane receptor Ki 8.05 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.65 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.80 WOMBAT-PK
Multidrug and toxin extrusion protein 1 Transporter IC50 4.48 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.49 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 6.50 PDSP
Alpha-1B adrenergic receptor GPCR Ki 5.99 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR Kd 6.59 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.08 CHEMBL
Alpha-1D adrenergic receptor GPCR AGONIST Ki 6.90 IUPHAR
5-hydroxytryptamine receptor 1A GPCR IC50 5.27 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 9.41 CHEMBL
Alpha-1A adrenergic receptor GPCR EC50 7.05 CHEMBL
Alpha-2A adrenergic receptor GPCR IC50 8.70 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 4.40 CHEMBL
Nischarin Unclassified Ki 6.95 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Ion channel BLOCKER IC50 4.40 IUPHAR
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Ion channel BLOCKER IC50 5.10 IUPHAR
Adrenergic receptor alpha-2 GPCR Ki 8.82 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel BLOCKER IC50 5 IUPHAR
Alpha-1B adrenergic receptor GPCR EC50 7.08 CHEMBL

External reference:

IDSource
4017850 VUID
N0000146207 NUI
D00281 KEGG_DRUG
4205-91-8 SECONDARY_CAS_RN
142432 RXNORM
4017849 VANDF
4017850 VANDF
C0009014 UMLSCUI
CHEBI:46631 CHEBI
CLU PDB_CHEM_ID
CHEMBL134 ChEMBL_ID
DB00575 DRUGBANK_ID
CHEMBL1705 ChEMBL_ID
D003000 MESH_DESCRIPTOR_UI
2803 PUBCHEM_CID
2624 INN_ID
516 IUPHAR_LIGAND_ID
MN3L5RMN02 UNII
27687 MMSL
381 MMSL
4478 MMSL
4479 MMSL
89106 MMSL
d00044 MMSL
000644 NDDF
004495 NDDF
372805007 SNOMEDCT_US
387121001 SNOMEDCT_US
62782004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9723 INJECTION, SOLUTION 500 ug INTRAVENOUS ANDA 21 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9724 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 21 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2127 TABLET 0.10 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2128 TABLET 0.20 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2129 TABLET 0.30 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-4241 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 19 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0871 PATCH 0.10 mg TRANSDERMAL ANDA 16 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0872 PATCH 0.20 mg TRANSDERMAL ANDA 16 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0873 PATCH 0.30 mg TRANSDERMAL ANDA 16 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3508 PATCH 0.10 mg TRANSDERMAL ANDA 21 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3509 PATCH 0.20 mg TRANSDERMAL ANDA 21 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3510 PATCH 0.30 mg TRANSDERMAL ANDA 21 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0031 PATCH 0.10 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0031 PATCH 0.10 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0032 PATCH 0.20 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0032 PATCH 0.20 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0033 PATCH 0.30 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0033 PATCH 0.30 mg TRANSDERMAL NDA 23 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-2572 TABLET 0.10 mg ORAL ANDA 18 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-2574 TABLET 0.30 mg ORAL ANDA 18 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8272 TABLET 0.20 mg ORAL ANDA 12 sections
CLONIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-708 TABLET 0.10 mg ORAL ANDA 20 sections
CLONIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-709 TABLET 0.20 mg ORAL ANDA 20 sections
CLONIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-710 TABLET 0.30 mg ORAL ANDA 20 sections
Clonidine HydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-257 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 26 sections
Clonidine HydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-257 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 26 sections
Clonidine HydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-302 TABLET, EXTENDED RELEASE 0.20 mg ORAL ANDA 26 sections
Clonidine HydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-302 TABLET, EXTENDED RELEASE 0.20 mg ORAL ANDA 26 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-042 TABLET 0.30 mg ORAL ANDA 20 sections
CLONIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10544-158 TABLET 0.20 mg ORAL ANDA 21 sections